Kornimate/medical-research-clean huggingface dataset:
acute mri in transient ischemic attack

Conditions: Ischemic Attack, Transient

Summary: the purpose of this study is to detect acute ischemic lesions in patients admitted with symptoms of transient ischemic attack (tia). diffusion weighted imaging (dwi) is today one of the best ways to detect ischemic lesions after tia. the problem is that this only gives the diagnosis in 30% of the cases. it is possible that the addition of arterial spin labeling (asl) perfusion imaging and diffusion tensor imaging will make it possible to give a more accurate diagnosis.

the purpose of this study is to detect acute ischemic lesions in patients admitted with symptoms of transient ischemic attack (tia). diffusion weighted imaging (dwi) is today one of the best ways to detect ischemic lesions after tia. the problem is that this only gives the diagnosis in 30% of the cases. it is possible that the addition of asl-perfusion imaging and diffusion tensor imaging will make it possible to give a more accurate and selective diagnosis of tia. patients admitted with clinical signs of tia can be included. patients will be examined with the tia protocol in reference to the standardized clinical care: 1. 1,5 tesla gradient echo and 3 tesla susceptibility weighted imaging (swi) to detect microbleed as sign of small vessel disease. 2. axial t2 flair to detect white matter lesions. 3. axial dwi to detect areas with impeded diffusion. (total scantime 10min) if no signs of ischemic lesions is detected the following additional research scan-protocol will be initiated: 1. perfusion without contrast: arterial spin labeling (asl) with the ability of showing signs of ischemia. 2. diffusion tensor imaging (dti): has a higher sensitivity than dwi in displaying local ischemic lesions. (total additional scantime 10min) all in all 20min in the scanner.

Eligibility criteria:
inclusion criteria: * clinical signs of tia * informed consent * no serious respiratory or cardiac implications exclusion criteria: * contraindications to mri

Keywords: diffusion tensor imaging
a study of gaboxadol in primary insomnia

Conditions: Primary Insomnia

Summary: to evaluate the safety and tolerability of gaboxadol in primary insomnia.

to obtain long-term safety data in elderly patients with gaboxadol.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of primary insomnia

Keywords: primary insomnia
contraceptive hormones and women with cystic fibrosis

Conditions: Cystic Fibrosis Exacerbations While on and Off Hormonal Contraception

Summary: primary objective our primary objective in this study is to evaluate satisfaction of hormonal contraception in this sample of women and to evaluate the impact that this hormonal contraceptive has on cystic fibrosis (cf) disease in women with regular menstrual cycles accompanied by cyclic exacerbations. we hypothesize: 1a) women with cf who perceive an overall benefit of hormonal contraception will be more satisfied than women with cf who do not perceive a benefit, 1b) women with cf who have cyclic exacerbations will have decreased pseudomonas aeruginosa mucoidy conversion while using hormonal contraception, 1c) women with cf who have cyclic exacerbations will have improved patient-reported quality of life indices while on hormonal contraception, and 1d) women with cf who have cyclic exacerbations will have improvement in pulmonary function tests while on hormonal contraception. secondary objective we plan to secondarily evaluate the cervical mucus of women with cf at the time of ovulation and compare it to that of healthy controls. we hypothesize that women with cf have ovulatory cervical mucus similar to healthy peers.


Eligibility criteria:
inclusion criteria: * female, reproductive age (18-40), cyclic cf exacerbations, regular menstrual cycles exclusion criteria: * pregnant, desires pregnancy, contra-indication to hormonal contraception, currently using hormonal contraception
efficacy and tolerability of enstilar® in daily practice

Conditions: Plaque Psoriasis

Summary: this study aims to assess how the enstilar® aerosol foam performs in daily real-life practice with regards to effectiveness and convenience of application to psoriasis plaques on body and extremities. in addition the profiles of patients prescribed enstilar® will be described, and preceeding, concomitant and follow-up management will be mapped. the study will be conducted in about 100 dermatology clinics all over germany,


Eligibility criteria:
inclusion criteria: * ≥ 18 years of age * psoriasis vulgaris * lesions on trunk and/or extremities of at least mild severity * treatment with enstilar® planned * signed informed consent to participate exclusion criteria: * enrolled in any interventional clinical trial * ongoing or recent treatment with any systemic psoriasis * ongoing or recent treatment with uv-therapy * ongoing or previous treatment with enstilar® * psoriasis of scalp only * other forms of psoriasis, e.g. erythrodermic or pustular psoriasis * more than 30% of surface area affected by psoriasis * any contraindications or known allergies to enstilar® or its ingredients * incapacitated patients under institutionalized care

Keywords: psoriasis vulgaris plaque topical calcipotriol foam spray
abg in blunt chest trauma

Conditions: Blunt Injury of Thorax

Summary: this study aims to determine the value of abg measurments in patients with blunt chest trauma and its role in prognosis of different outcomes and the results would aid the emergency physicians to speed up the management and reduce the cost of diagnosis


Eligibility criteria:
inclusion criteria: - all patient with polytrauma or blunt trauma to chest and thoraco-abdominal area from both genders are included in the study exclusion criteria: * shocked patients whom were intubated ,patients that had pulmonary disease or heart diseases ,penetrating chest injury ,pregnant female ,patients who do not want to participate in the study
efficacy and safety of azd4547 versus paclitaxel in patients with advanced gastric or gastro-oesophageal cancer

Conditions: Gastro-oesophageal Junction Cancer; Gastric Cancer

Summary: the purpose of this study is to assess the efficacy, safety and tolerability of azd4547 compared with paclitaxel in patients with advanced gastric or lower-oesophageal cancer whose tumours are found to have fgfr2 polysomy or gene amplification.

a randomised open-label phase iia study to assess the efficacy and safety of azd4547 monotherapy versus paclitaxel in patients with advanced gastric or gastro-oesophageal junction cancer with fgfr2 polysomy or gene amplification (shine study). patients were to be assigned to strata by fgfr2 status of: polysomy, low or high gene amplification.

Eligibility criteria:
inclusion criteria: * female or male aged 25 or over * histological diagnosis of locally advanced or metastatic gastro adenocarcinoma (including adenocarcinoma of the lower third of the oesophagus or the gastro oesophageal junction ) * radiographically confirmed progression after 1 prior chemotherapy or chemoradiotherapy for gastric cancer. suitable for and expected to benefit from paclitaxel monotherapy. * at least one lesion, not previously irradiated, that has baseline at least 10mm in the longest diameter for non nodal lesions and is assessed by computerised tomography (ct) or magnetic resonance imaging (mri) * provision of either an archival tumour sample or a fresh tumour sample for confirmation of fgfr2 polysomy/gene amplification exclusion criteria: * prior exposure to azd4547 or history of hypersensitivity other drugs similar in structure or class to azd4547. hypersensitivity to paclitaxel or formulated in cremophor el (polyoxyethylated castor oil) * prior taxane treatment for gastric cancer with the exception of adjuvant/neo-adjuvant therapy given \> 6 months; major surgery, radiotherapy with wide field of radiation or any cancer treatment within 4 weeks before the first dose of the study treatment * with the exception of alopecia, any unresolved toxicities from prior therapy with a common terminology criteria for ae (ctcae) grade \>1 at the time of starting study treatment. * blood and echocardiogram (ecg) readings that are deemed to be abnormal by falling outside of the reference ranges in the protocol inclusion/exclusion section. * taking other regular medication that are predicted to interact with azd4547 due to their route of metabolism.

Keywords: gastro-oesophageal junction cancer gastric cancer lower third oesophageal cancer polysomy amplification fgfr
identifcation of biomarkers for active pulmonary tuberculosis

Conditions: Tuberculosis; Diagnosis

Summary: this experiment is designed to analyze the metabolites in body fluids from patients with active tuberculosis and latent tuberculosis infection also with health volunteer, then combine the metabolic product features with clinical characteristics, to develop a kind of metabolites targets to evaluate the progress in tuberculosis, thus provide a basis for further utilization of humoral metabolites in the diagnosis of tuberculosis.


Eligibility criteria:
inclusion criteria: * patients with active tuberculosis and latent tuberculosis infection exclusion criteria: * have other serious health problems
gait and balance of diabetes type 2 patients

Conditions: Diabetes Type 2

Summary: type 2 diabetes is one of the fastest growing public health problems in both developed and developing countries. it is estimated that the number of people with diabetes in the world will double in coming years, from 171 million in 2000 to 366 million in 2030.the role of physiotherapy in diabetic care is to reduce immobilisation effects, to maintain functional capacity and to minimise diabetes-related complications. the physiotherapist also has a role in providing advice about exercise and daily living activities. the fundamental principle of rehabilitation is to improve quality of life while diminishing the health care burden. by reducing the heightened risk of falling, the fall related injuries and the fear of falling one could improve quality of life in diabetic patients and reduce health care costs. the goal of this study is to investigate the effectiveness of gait and balance training in pre frail subgroup diabetes patients. our program is based on recommendations of robertson et al.(2002) and page et al.(2002) the investigators randomly assign patients in a control group (no treatment) or in a treatment group. the treatment program consists of two group sessions per week over 12 weeks. patients were encouraged to perform specific home exercises. after this 12-week program, patients were asked to continue their exercises. the effect of the treatment will be evaluated after the treatment program and after a 6-month follow up.


Eligibility criteria:
inclusion criteria: * past or present patient from the university hospital in geneva * diagnosed with diabetes by the medical doctor (glycaemia \> 7 mmol on two different tests on an empty stomach) * presence of a peripheral neuropathy (vibration perception ≤ 4) exclusion criteria: * patients with a foot ulcer at the moment of intake * patients with orthopaedic or chirurgical problems influencing gait parameters * patients with a non diabetic neuropathy (charcot, alcohol, thyroid dysfunction) * patients with neurological problems influencing gait parameters * patients with incapacity to walk without a walking aid

Keywords: treatment efficacy diabetes gait balance
laparoscopic vs robotic-assisted radical prostatectomy

Conditions: Prostate Cancer

Summary: this randomized trial was designed to address the lack of high-quality literature comparing robotic-assisted (rarp) and laparoscopic (lrp) radical prostatectomy (rp). purpose: the lap-01 trial compares outcomes between rarp and lrp.

lap-01 is the first multicenter, prospective randomized, patient-blinded controlled trial comparing robotic-assisted and conventional laparoscopic radical prostatectomy. the investigation include an extensive evaluation of clinical, oncological, functional and quality of life related data by means of validated patient-reported outcome measures. the primary outcome is the assessment of time to continence restoration at 3 months. this is evaluated by an assessment of a pad diary completed daily by each patient from the time of catheter removal until restoration of continence. secondary endpoints include continence and erectile function, as well as quality of life (eortc-qlq-c30, eortc-qlq-pr25), patient satisfaction and hospital anxiety and depression scale (hads) at 1, 3, 6 and 12 months after surgery in addition to oncological outcomes up to 3 years follow-up. with 782 enrolled patients it is the largest trial carried out till date on this topic.

Eligibility criteria:
inclusion criteria * histological verified prostate carcinoma (first diagnosis) * indication for primary curative radical prostatectomy * age ≤ 75 years * patient agrees to randomisation * patient is able to fill in the questionnaires on his own * patient is willing to provide written informed consent exclusion criteria: * insufficient knowledge of german * severe cognitive impairment * obesity (bmi \> 35) * current existing severe comorbidities (e.g. liver cirrhosis, second malignancy or relapse of every kind) * tumor stage: t4 * previous malignancy (≤ 3 years before trial participation) * neoadjuvant therapy (hormons) within the last 3 months before participation in the trial * patient is immuno-compromised * history of intermittent urinary self-catheterization within the last year * psychological disorders (dementia, chronic depression, psychosis) * any of the following treatments ≤ 3 months before trial participation: surgery of the sigmoid colon, extended haemorrhoid resection, transurethral needle ablation of the prostate (tuna), osteosynthesis of the pelvis, salvage prostatectomy * patients with chronic urinary infection * dialysis patients * lacking willingness for data storage and handling in the frame of the trial protocol/aims

Keywords: davinci robotic-assisted prostatectomy laparoscopy continence
the effect of reiki and acupressure on pain, anxiety and vital signs

Conditions: Coronary Artery Disease

Summary: this research aims to determine the effects of reiki and acupressure applied after percutaneous coronary intervention on pain, anxiety and vital signs during femoral catheter extraction.

in this study, 84 patients with percutaneous coronary intervention were assigned to the reiki, acupressure and control groups by block randomization method.in the acupressure group (n=28) the heart meridian 7th point (ht7) large intestine meridian 4th point (li4) and pericardial meridian 6th point (pc6) will be applied to a total of three points.depending on the preparation and compression time on each point, the session duration of each patient will be 18 minutes on average.in the reiki group (n=28) the crown chakra (top of the head), the forehead chakra (above the forehead), the throat chakra (above the throat), the heart chakra (the middle of the chest), the solar plexus (under the chest, above the navel), the sacral chakra (below the navel) and the root chakra (above the coccyx) will be applied to the region of the 7 chakra points on.in the reiki group, the reiki application time will take 21 minutes on average.routine care will be applied to the control group (n=28).pre-test data of patients in the acupressure, reiki and control groups will be collected 30 minutes before femoral catheter extraction after percutaneous coronary. posttest data will be collected five minutes after femoral catheter extraction. data will be collected using the "personal information form", "visual analog scale", "state anxiety inventory" and "vital signs evaluation form".

Eligibility criteria:
inclusion criteria: * 18 years and over, * percutaneous coronary intervention (pci) for the first time, * previously planned pci (elective patients), * no additional procedure to percutaneous coronary intervention, * awake and conscious during percutaneous coronary intervention (not taking sedatives) * a single sandbag is placed on the intervention area, * able to lie flat on his back (without respiratory distress), * hemodynamically stable (absence of chest pain and arrhythmia), * no analgesic drug administered at least four hours before, * no complications such as hematoma or bleeding in the operation area, * no deformity or lesion in the areas where acupressure will be applied, * no previous experience of acupressure and reiki application, * not diagnosed with anxiety disorder and not receiving medical treatment, * literate, * have sufficient communication skills and * those who signed the informed consent form to participate exclusion criteria: * emergency patients whose pci was not planned beforehand, * bleeding, hematoma, etc. at the femoral intervention site during and after the procedure. developing complications, * any deformity, wound or lesion in the areas where acupressure will be applied, * coronary angiography only, * thrombocyte level less than 100,000 mg/dl, * those who did not sign the informed consent form to participate in the study

Keywords: percutaneous coronary intervention acupressure reiki pain anxiety vital signs
detecting fluid accumulation with a wearable bioimpedance sensor

Conditions: Overhydration; Kidney Failure; Edema

Summary: the investigation is a prospective cohort study, where two patient groups will be monitored by a wearable bioimpedance sensor during their scheduled treatment. the overall objective is to assess the bioimpedance sensor's ability to detect local and systemic fluid accumulation. sub-investigation a will investigate the ability of the device to detect fluid accumulation in patients with stable chronic kidney disease undergoing regular and planned hemodialysis. sub-investigation b will investigate the ability of the device to track hydration status in patients scheduled for an "intensive" dialysis treatment regime, due to severe overhydration.

in sub-investigation a, patients will be monitored for at least 10 consecutive dialysis sessions, and for a minimum of 3 weeks. patients will wear two sensors (upper back and lower anterior leg). in sub-investigation b, patients will use the device throughout their whole treatment period, and for most patients, this will correspond to 2-6 dialysis treatments over 3 to 10 days. patients will wear four patches (upper back, lateral thorax, anterior thigh, and lower anterior leg).

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * regular hemodialysis (≥ 2 times weekly) with ultrafiltration volume ≥ 1 liter (sub-investigation a) * scheduled for intensive dialysis treatment due to severe overhydration (sub-investigation b) exclusion criteria: * known allergies or skin sensitivities to electrode hydrogel and/or acrylic adhesives * implantable pulse generators such as pacemakers and defibrillators, and/or use of other electrical medical equipment for which an interaction effect with the investigational device cannot be ruled out. * patients undergoing mri * breached skin at patch mounting area * pregnancy * any medical or psychiatric condition, which in the opinion of the investigator precludes participation

Keywords: hydration
to compare ofloxacin with azitromycin for pelvic inflammatory disease (pid) treatment

Conditions: Pelvic Inflammatory Disease

Summary: objective: to compare two oral treatments: ofloxacin + metronidazole, and azitromycin +metronidazole in outpatients with pelvic inflammatory disease. materials and methods: two hundred patients divided to two groups( a , b). group a (treated by ofloxacin 400 mg. + metronidazole 500mg) and group b (a single dose of oral azitromicine 1gr + metronidazole 500mg) for 10 days, were compared in terms of side effects and efficacy

two hundred patients divided to two groups( a , b). group a (treated by ofloxacin 400 mg. + metronidazole 500mg) and group b (a single dose of oral azitromicine 1gr + metronidazole 500mg) for 10 days, were compared in terms of side effects and efficacy

Eligibility criteria:
inclusion criteria:eligibility criteria were having three out of five following symptoms: a-lower abdominal pain, b-vaginal discharges, c- adnexal tenderness, d-cervical motion tenderness (cmt), e-cervisitis. - exclusion criteria:excluding criteria were as follows: a-unmarried women, b-pregnant women, c-women with infection during menstruation, d- history of abortion or miscarriage during the last month, e-underlying diseases such as diabetes, f-used antibiotics in the last month, or allergy to the antibiotics used in the study, g-history of pelvic inflammatory disease within the last year, and h- suspicion of being multi partner. -

Keywords: pid, ofloxacin, azitromicine, metronidazole
an extension study to evaluate the long term safety, tolerability and efficacy of aliskiren compared to enalapril in pediatric hypertensive patients 6-17 years of age

Conditions: Hypertension

Summary: the purpose of this study is to evaluate in a randomized, double-blind fashion, the long-term safety, tolerability and efficacy profile of aliskiren compared to the active comparator enalapril in children, 6 - 17 years old with hypertension (mssbp ≥ 95th percentile for age, gender and height, at baseline in study cspp100a2365). patients will be randomized to receive either aliskiren or enalapril. weight-group based doses of aliskiren or enalapril will be administered once daily and children will receive study medication in a double-blind manner. this study is being conducted to support monotherapy registration of aliskiren for the treatment of hypertension in pediatric patients 6-17 years of age (age at baseline in study cspp100a2365).


Eligibility criteria:
inclusion criteria: * mssbp (mean of 3 systolic blood pressure measurements) must be ≥ 95th percentile for age, gender and height, at visit 2 (randomization), in study cspp100a2365 * must be ≥ 20 kg and ≤ 150 kg at visit 2 (randomization), in study cspp100a2365 * must be able to swallow minitablets (2mm in diameter) administered in soft food * successful completion of phase 1 (dose response phase) and at least 1 week of phase 2 (placebo withdrawal phase) of the cspp100a2365 protocol, with no serious drug-related adverse event(s). exclusion criteria: * patient receiving immunosuppressant medication (e.g. cyclosporine, mmf, etc) other than oral/topical steroids, for any medical condition * current diagnosis of heart failure (nyha class ii-iv) or history of cardiomyopathy or obstructive valvular disease * mssbp ≥ 25% above the 95th percentile * second or third degree heart block without a pacemaker * ast/sgot or alt/sgpt \>3 times the upper limit of the reference range * total bilirubin \> 2 times the upper limit of the reference range * creatinine clearance \< 30 ml/min/1.73m² (calculated using modified schwartz formula to estimate glomerular filtration rate \[gfr\]), based on the serum creatinine concentration obtained at the screening visit) * wbc count \< 3000/mm³ * platelet count \< 100,000/mm³ * serum potassium \> 5.2 meq/l * other protocol-defined inclusion/exclusion criteria may apply

Keywords: pediatric hypertension primary hypertension secondary hypertension
a single-dose, 2-period, 2-treatment, 2-way crossover bioequivalency study of ropinirole 0.25 mg tablets under fed conditions

Conditions: Parkinson's Disease; Restless Leg Syndrome

Summary: the objective of this study was to assess the single dose bioequivalence of roxane's ropinirole tablets,0.25 mg, to requip tablets, 0.25 mg (glaxosmithkline) under fed conditions using a single dose, randomized, 2-treatment, 2-period, 2-sequence cross-over design.

the objective of this study was to assess the single dose bioequivalence of roxane's ropinirole tablets,0.25 mg, to requip tablets, 0.25 mg (glaxosmithkline) under fed conditions using a single dose, randomized, 2-treatment, 2-period, 2-sequence cross-over design.

Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on the physical examination, medical history, or clinical laboratory results during screening exclusion criteria: * positive test for hiv, hepatitis b, or hepatitis c. * treatment with known enzyme altering drugs. * history of allergic or adverse response to ropinirole or any other comparable product.